Carlo Medici, Chief Executive Officer
Carlo Medici serves as the CEO of Alzeca. He has over 30 years of experience in executive roles in the pharmaceutical, diagnostic, and medical devices industry. More recently, he was CEO at Bellco where he was responsible for the definition and implementation of the strategic plan aimed at positioning the company as a leader in the dialysis worldwide market. Prior to this he spent over 12 years at Bracco as CEO of Bracco Diagnostics Inc., a leader in the diagnostic imaging market (contrast agents for X-Ray/CT, MRI, and Ultrasound, radio tracers, and injector systems). In addition to the executive role for the North American market, he assumed a global role as head of commercial operations for Bracco Imaging, the parent company. In this capacity, he was responsible for all marketing, sales, and business development strategies, with sales in excess of $1 billion and direct presence in North and most of South America, most of Europe and China, and indirect presence in rest of Europe, Japan and RoW through distributors and joint-ventures. During his tenure, Bracco dramatically increased its market share in the U.S. in both X-Ray/CT and MRI contrast agents. Prior experiences include Vice President of Clinical Trials and Corporate Vice President of Sales, Marketing and Customers Satisfaction at Covance and several roles at Hofmann-La Roche, including President of Roche Diagnostics where he led the launch of the PCR assays that transformed the in-vitro diagnostic market in the 90’s. Mr. Medici holds a BS degree in Chemistry and Pharmaceutical Technology.
Thomas Hale, Chief Operating Officer
Thomas Hale has over 30 years in the pharmaceutical business and has been involved in drug delivery research, dosage form and process development, engineering research, and clinical and global manufacturing through his career. He worked in Engineering R&D, Formulation Development, Material Characterization, Clinical Supply Manufacture, and headed a variety of managerial positions in global process and product development for 20 years.
Thomas founded Hale Technologies in 2002 and has been involved in the development of new pharmaceutical and biotechnology products in the US, Europe, and South America. He has been responsible for 13 NDAs and equivalent global submissions and supported the products through launch and manufacturing.
Brenda Fielding, Vice-President of Regulatory Affairs
Brenda Fielding brings over 30 years of experience in biotech and pharma, more than 20 of which have been in the area of Regulatory Affairs and Quality. Before coming to Alzeca, Brenda was Founder & President of Regulus Pharma Consulting in Boulder, Colorado. Prior to Regulus, she held senior management positions in a number of US pharmaceutical and biotechnology companies. She has been involved in the successful clinical development of novel drugs, biologics, and drug delivery systems over a wide range of areas, including oncology, anti-infectives, immunotherapeutics, and ophthalmology.